Royalty Report: Drugs, DNA, Antibody – Collection: 203789

License Grant

The University grants the Licensee and its Subsidiaries an exclusive, royalty-bearing license under the Licensor Know-How and Patent Rights to make, have made, use, offer for sale, sell, import and commercialize Licensed Products and Platform Products in the Field of antibody cell therapy products, in the Territory.

License Property

The IP includes B7H6 – an antibody. NKG2D –  a major recognition receptor for the detection and elimination of transformed cells.  NKP30  – a protein which helps to eliminate transformed  cells  and TIM Products  means any DNA or protein product with a DNA or protein sequence.

Field of Use

The Licensee is a Biotechnology company developing products in the field of Gene Therapy, Cell Therapy and Pharmaceuticals.

License Grant

The Licensor of England grants to the Licensee the following licenses under the Winter Patent
– a non-exclusive world-wide license to exploit the Winter Patent commercially in any way whatsoever by the use of the Reshaping Process in the Fields and by the commercial exploitation in the Fields of any resulting antibodies provided always that any such exploitation does not involve the antibodies detailed.
– a non-exclusive sub-license under the Boss Patents to the extent required to enable the licensee to use the Reshaping Process to produce Products from mammalian cells and for no other purpose.

License Property

Licensor has certain patent rights in respect of the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another.

The Reshaping Process shall mean the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another as described in the Winter Patent.

The Products shall mean end products produced either directly or indirectly from antibodies which have been modified using the Reshaping Process and which are in a form capable of being marketed or sold upon a commercial basis.

Winter patents relate to Recombinant DNA products and Methods.

Boss patents relate to Multichain Polypeptides or Proteins and Processes for their Production Expression of multichain proteins, such as antibodies, in single hose cells.

Field of Use

The Fields shall mean the field of human therapy or prophylaxis and human in vivo and in vitro diagnostics.

License Grant

The English Licensor hereby grants to Licensee a world-wide non-exclusive licence under the Intellectual Property to develop, manufacture, market and sell Product in the Territory, there shall be no right to sublicense the rights granted hereunder.

License Property

US Patents Rights
5,981,216 – Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
5,770,359 – Recombinant DNA sequences, vectors containing them and method for the use thereof
5,827,739 – Recombinant DNA sequences, vectors containing them and method for the use thereof
5,591,639 – Recombinant DNA expression vectors
5,658,759 – Recombinant DNA expression vectors

Product means a monoclonal antibody to a bacterial cell surface adhesion known as Aurexis(TM) of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials, or any formulation containing the same.

Intellectual property and materials relating to the expression of recombinant monoclonal antibodies to bacterial surface proteins for use in the manufacture of Aurexis.

Field of Use

Aurexis is currently being evaluated in a Phase II clinical trial as a first-line therapy, in combination with standard of care antibiotics, to treat serious, life-threatening Staphylococcus aureus, or S. aureus, bloodstream infections in hospitalized patients.